多隻未有盈利生物股創新高後急吐 康希諾及邁博倒跌12%-13%
近期狂炒仍未有任何盈利生物「B類股」今天普遍由高位掉頭急吐,康希諾生物-B(06185.HK)承過去連續七天破頂強勢,今天再飆升16%高見285.8元(較去年3月上市價22元累飆近12倍)遇阻,午後獲利盤湧現,股價掉頭曾失守10天線(193.8元),曾急吐23%低見190元,現造216.8元,急吐12%,成交急增至788萬股,創逾一個月高,涉資18.47億元。
邁博藥業-B(02181.HK)本周一曾飆升至1.8元創上市新高遇阻反覆回落,今天低見1.25元,現造1.3元,急吐13%,成交1,436萬股。信達生物-B(01801.HK)高見46.7元,受制本周二盤中所創上市高位46.8元,掉頭低見42元,現造42.4元,倒跌8.1%。
去年底才掛牌的康寧傑瑞製藥-B(09966.HK)今早高開見24.15元上市新高遇阻,掉頭低見20.6元,現造21.55元,倒跌6.7%。
華領醫藥-B(02552.HK)日前受制牛熊線,今天股價反覆續吐2.4%報4.95元。諾誠健華-B(09969.HK)再撲昨天盤中所創上市高位16.8元未能成功突破,掉頭低見15.22元(剛為10天線),現造15.46元,倒跌4.8%。中國抗體製藥-B(03681.HK)高見4.95元創半年高遇阻,掉頭低見4.25元,現造4.36元,倒跌1%。上周五才以每股15.36元上市的沛嘉醫療-B(09996.HK)高見31.25元再創上市新高遇阻,掉頭低見26.15元,現造27.8元,倒跌5.1%。
不過,君實生物醫藥-B(01877.HK)繼昨天整固後,今天股價再創上市新高,最高見49.7元,現造45.85元,回升4.3%。
至於大股東藉股價反覆探頂以每股127.18元(較昨天收市價折讓4.9%)配售6,000萬股的高藥明生物(02269.HK)由上市高位140.8元掉頭連吐第三天,最低見129元,現造131.4元,續吐1.7%,股價失守10天線(132.6元),成交受配股上板帶動增至7,508萬股。另外,藍籌中生製藥(01177.HK)繼昨天升至12.66元受制3月所創52周高位後,今天股價回吐4%報11.9元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.